RecruitingPHASE1, PHASE2NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Intervention
- AZD3470(drug)
- Enrollment
- 161 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- Research Site, Duarte, California, United States
- Research Site, Miami, Florida, United States
- Research Site, Atlanta, Georgia, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, New York, New York, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Houston, Texas, United States
- Research Site, Adelaide, Australia
- Research Site, Fitzroy, Australia
- Research Site, Nedlands, Australia
- Research Site, South Brisbane, Australia
- Research Site, Waratah, Australia
- Research Site, Beijing, China
- Research Site, Guangzhou, China
- Research Site, Shanghai, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06137144 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation